arrow
L

Luis E. Raez

Memorial Healthcare System
H指数:45
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data study”- the Lancet Regional Health—Americas 2025; Volume 49: 101172; DOI: 10.1016/j.lana.2025.101172

勘误:“男性晚期肺癌中创新疗法可及性的临床和经济影响:一项基于人群的二次数据研究”——《柳叶刀·区域健康—美洲》2025;第49卷:101172;DOI:10.1016/j.lana.2025.101172

2025-11-140
OAAI
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast

II期COPERNICUS研究:皮下注射Amivantamab联合Lazertinib作为一线治疗,或与化疗联合作为二线治疗,用于EGFR突变非小细胞肺癌的播客视频

2025-10-110
OA
Clinicogenomic and treatment outcomes in RET fusion-positive NSCLC: A multicenter study in Latin American Hispanic patients

临床基因组学和治疗结果在RET融合阳性NSCLC中:一项在拉丁美洲西班牙裔患者中的多中心研究

2025-09-010
OAAI
Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data study

拉丁美洲男性晚期肺癌中创新疗法可获得性的临床与经济影响:一项基于人群的二次数据研究

2025-07-020
PRE
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)

非小细胞肺癌(NSCLC)中获得性EGFR耐药突变的发生率及其分子相关性

2025-04-170
PRE
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

曲美替尼通过Id1下调使KRAS突变型肺腺癌肿瘤对PD-1/PD-L1轴阻滞敏感

2024-04-201
OAAI
Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis
2024-01-231
OAAI